



**NATIONAL
QUALITY FORUM**

Driving measurable health
improvements together

Behavioral Health and Substance Use, Fall 2020 Measure Review Cycle Measure Evaluation Standing Committee Meeting

Samuel Stolpe, PharmD, MPH, Senior Director
Mike DiVecchia, PMP, MBA, Senior Project Manager
Monika Harvey, PMP, MBA Project Manager
Tamara Funk, MPH, NQF Manager
Hannah Bui, MPH, NQF Manager
Udobi Onyeuku, MSHA, NQF Analyst

February 11, 2021

*Funded by the Centers for Medicare and Medicaid Services under contract HHSM-500-2017-000601
Task Order HHSM-500-T0001.*

Welcome

Housekeeping Reminders

- This is a Ring Central meeting with audio and video capabilities
- Optional: Dial **(470) 869-2200** and enter Meeting ID: **148 121 6965**
- Please place yourself on mute when you are not speaking
- We encourage you to use the following features
 - ▣ Chat box: to message NQF staff or the group
 - ▣ Raise hand: to be called upon to speak
- We will conduct a Committee roll call once the meeting begins

If you are experiencing technical issues, please contact the NQF project team at behavioralhealth@qualityforum.org



Agenda

- Roll Call
- Recap of Day 1
- Voting Test
- Consideration of Candidate Measures
- Related and Competing Measures
- NQF Member and Public Comment
- Next Steps
- Adjourn

Behavioral Health and Substance Use Fall 2020 Cycle Standing Committee

- Harold Pincus, MD (Co-chair)
- Michael Trangle, MD (Co-chair)
- Loretta (Ann) Bostic, DNP, MBA, APRN, CRNA, PMHNP-BC
- Caroline Carney, MD, MSc, FAMP, CPHQ
- Vitka Eisen, MSW, EdD
- Julie Goldstein Grumet, PhD
- Benjamin Han, MD, MPH
- Morissa Henn, MPH, DrPH
- Lisa Jensen, DNP, APRN
- Caitlyn Kjolhede, BSN, MBA
- Kraig Knudsen, PhD (*inactive*)
- Barbara Lang, LPC, LISAC
- Michael R. Lardieri, LCSW
- Raquel Mazon Jeffers, MPH, MIA
- Brooke Parish, MD
- David Pating, MD
- Vanita Pindolia, PharmD
- Chantelle Rice Collins, OTD, OTR/L, CDCES
- Andrew Sperling, JD
- Jeffery Susman, MD
- Allen Tien, MD
- Patrick Triplett, MD
- Heidi Waters, MBA, PhD
- Bonnie Zima, MD, MPH

Recap of Day 1

Voting Test

Consideration of Candidate Measures

3589 Prescription or administration of pharmacotherapy to treat opioid use disorder (OUD)

- **Measure Steward/Developer:** RTI International

- ▣ New measure

- **Brief Description of Measure:**

- ▣ This measure reports the percentage of a provider's patients who were Medicaid beneficiaries ages 18 to 64 with an OUD diagnosis who filled a prescription for, or were administered or ordered, a FDA-approved medication to treat OUD within 30 days of the first attributable OUD treatment encounter with that provider.

3590 Continuity of Care After Receiving Hospital or Residential Substance Use Disorder (SUD) Treatment

- **Measure Steward/Developer:** RTI International

- ▣ New measure

- **Brief Description of Measure:**

- ▣ Percentage of Medicaid discharges, ages 18 to 64, being treated for a substance use disorder (SUD) from an inpatient or residential provider that received SUD follow-up treatment within 7 or 30 days after discharge. SUD follow-up treatment includes outpatient, intensive outpatient, or partial hospitalization visits; telehealth encounters; SUD medication fills or administrations; or residential treatment (after an inpatient discharge). Two rates are reported: continuity within 7 and 30 days after discharge.

Related and Competing Discussion

Related and Competing Measures

- If a measure meets the four criteria **and** there are endorsed/new related measures (same measure focus **or** same target population) or competing measures (both the same measure focus **and** same target population), the measures are compared to address harmonization and/or selection of the best measure.

	Same concepts for measure focus-target process, condition, event, outcome	Different concepts for measure focus-target process, condition, event, outcome
Same target population	Competing measures-Select best measure from competing measures or justify endorsement of additional measure(s).	Related measures-Harmonize on target patient population or justify differences.
Different target patient population	Related measures-Combine into one measure with expanded target patient population or justify why different harmonized measures are needed.	Neither harmonization nor competing measure issue.



Related and Competing Measures (continued)

- Related and competing measures will be grouped and discussed after recommendations for all related and competing measures are determined. Only measures recommended for endorsement will be discussed.
- Committee will not be asked to select a best-in-class measure if all related and competing measures are not currently under review. Committee can discuss harmonization and make recommendations. Developers of each related and competing measure will be encouraged to attend any discussion.



0576 Related Measures

- **2605** Follow-Up After Emergency Department Visit for Mental Illness or Alcohol and Other Drug Abuse or Dependence (National Committee for Quality Assurance)
- **3489** Follow-Up After Emergency Department Visit for Mental Illness (National Committee for Quality Assurance)



3205 Related Measures

- **1879** Adherence to Antipsychotic Medications for Individuals with Schizophrenia (Mathematica)



3589 Related Measures

- **3175** Continuity of Pharmacotherapy for Opioid Use Disorder (University of California, Los Angeles)
- **3400** Use of Pharmacotherapy for Opioid Use Disorder (OUD) (Mathematica)



3590 Related Measures

- **0004** Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (National Committee for Quality Assurance)
- **0576** Follow-Up After Hospitalization for Mental Illness (National Committee for Quality Assurance)
- **1937** Follow-Up After Hospitalization for Schizophrenia (7- and 30-day) (National Committee for Quality Assurance)
- **2605** Follow-Up After Emergency Department Visit for Mental Illness or Alcohol and Other Drug Abuse or Dependence (National Committee for Quality Assurance)
- **3312** Continuity of Care After Medically Managed Withdrawal from Alcohol and/or Drugs (Mathematica)
- **3453** Continuity of Care after Inpatient or Residential Treatment for Substance Use Disorder (SUD) (National Committee for Quality Assurance/The Lewin Group)

NQF Member and Public Comment

Next Steps



Measure Evaluation Process After the Measure Evaluation Meeting

- Staff will prepare a draft report detailing the Committee's discussion and recommendations
 - ▣ This report will be released for a 30-day public and member comment period
- Staff compiles all comments received into a comment table which is shared with developers and Committee members
- Post-comment call: The Committee will reconvene for a post-comment call to discuss comments submitted
- CSAC meets to endorse measures
- Opportunity for public to appeal endorsement decision

Activities and Timeline – Fall 2020 Cycle

*All times ET

Meeting	Date, Time
Draft Report Comment Period	March 22 – April 20, 2021
Committee Post-Comment Web Meeting	May 24, 2021, 12:00 PM – 2:00 PM
CSAC Review	June 29 – June 30, 2021
Appeals Period (30 days)	July 7 – August 5



Spring 2021 Cycle Updates

- Intent to submit deadline was January 5, 2021
- 1 measure submitted for maintenance of endorsement
- Topic areas
 - ▣ Opioid Use Disorder



Project Contact Info

- Email: behavioralhealth@qualityforum.org
- NQF phone: 202-783-1300
- Project page:
[http://www.qualityforum.org/Behavioral Health and Substance Use.aspx](http://www.qualityforum.org/Behavioral_Health_and_Substance_Use.aspx)
- SharePoint site:
[https://prod.qualityforum.org/portfolio/BehavioralHealthSubstance Use/SitePages/Home.aspx](https://prod.qualityforum.org/portfolio/BehavioralHealthSubstanceUse/SitePages/Home.aspx)

Questions?

THANK YOU.

NATIONAL QUALITY FORUM

<http://www.qualityforum.org>